Vicuron Pharmaceuticals Inc.'s stock soared 21.9 percent Thursday after the firm said it would seek regulatory approval later this year on favorable data from a Phase III program of once-weekly dalbavancin in skin and soft-tissue infections caused by Gram-positive bacteria. (BioWorld Today)